Taglich Brothers Initiates Zynex, Inc.

Taglich Brothers Initiates Zynex, Inc.
 
NEW YORK, NY  -- (Marketwired) -- 08/22/17 --  Taglich Brothers, Inc.
announces that it has initiated coverage of Zynex, Inc. (OTCQB:
ZYXI).

Zynex, Inc., headquartered in Lone Tree, Colorado provides
FDA-cleared electrotherapy medical devices used for pain management
and rehabilitation. The company is primarily focused on selling and
marketing its NexWave and InWave electrotherapy product, as well as
consumable supplies for electrotherapy products. The company operates
two subsidiaries, Zynex Medical™, which provides electrotherapy
devices and consumable products for home use and Zynex Monitoring
Solutions™, which is developing a blood volume-monitoring device for
use in hospitals and outpatient surgical centers.

The complete 17-page report is available at www.taglichbrothers.com.

Taglich Brothers, Inc. is a full-service broker dealer focused
exclusively on microcap companies. The Company defines the microcap
segment of the equity market as companies with less than $250 million
in market capitalization. Taglich Brothers currently offers
institutional and retail brokerage services, investment banking and
comprehensive research coverage to the investment community.

We do not undertake to advise you as to changes in figures or our
views. This is not a solicitation of any order to buy or sell.
Taglich Brothers, Inc. is fully disclosed with its clearing firm,
Pershing, LLC, is not a market maker and does not sell to or buy from
customers on a principal basis. The above statement is the opinion of
Taglich Brothers, Inc. and is not a guarantee that the target price
for the stock will be met or that predicted business results for the
company will occur. There may be instances when fundamental,
technical and quantitative opinions contained in this report are not
in concert. We, our affiliates, any officer, director or stockholder
or any member of their families may from time to time purchase or
sell any of the above-mentioned or related securities. Analysts and
members of the Research Department are prohibited from buying or
selling securities issued by the companies that Taglich Brothers,
Inc. has a research relationship with, except if ownership of such
securities was prior to the start of such relationship, then an
Analyst or member of the Research Department may sell such securities
after obtaining expressed written permission from Compliance. All
research issued by Taglich Brothers, Inc. is based on public
information. As of the date of this report, we, our affiliates, any
officer, director or stockholder, or any member of their families do
not have a position in the stock of the company mentioned in this
report. Taglich Brothers, Inc. does not currently have an Investment
Banking relationship with the company mentioned in this report and
was not a manager or co-manager of any offering for the company with
in the last three years. All research issued by Taglich Brothers,
Inc. is based on public information. In July 2017, the company paid
Taglich Brothers a monetary fee of $4,500 (USD) representing payment
for the creation and dissemination of research reports for three
months. In December 2017, the company will begin paying Taglich
Brothers a monthly monetary fee of $1,500 (USD) for the creation and
dissemination of research reports.


Contact:
Rick Oh
Taglich Brothers, Inc.
631-757-1500
Press spacebar to pause and continue. Press esc to stop.